Private Equity, VC & Investor
Breega vs SFC Capital
Structured technology and market comparison · 2026
Direct Feature Comparison
Breega · vs · SFC CapitalEuropean and African early-stage venture capital fund manager.
UK seed investor and SEIS/EIS angel fund manager.
Analyze all overlapping signals and tech stacks for Breega and SFC Capital
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Breega and SFC Capital?
When comparing Breega and SFC Capital, both platforms operate within the Private Equity, VC & Investor ecosystem. Breega is positioned as European and African early-stage venture capital fund manager, whereas SFC Capital focuses on UK seed investor and SEIS/EIS angel fund manager. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Breega and SFC Capital?
When evaluating Breega and SFC Capital, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Breega and SFC Capital compare?
Breega is headquartered in FR (founded in 2013) with 10–49 employees. SFC Capital is based in GB (founded in 2012) with 10–49 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Breega vs SFC Capital
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Breega
Recent Signals
- ·EU-Startups (European Venture)Funding
Cori Clinical Raises €3.8M to Accelerate Clinical Trials
London-based Cori Clinical, a startup providing an AI-powered intelligence layer for clinical trials, has raised €3.8 million in a Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use the funds to expand delivery capacity, grow its team, and deepen regulatory and clinical intelligence in its platform. Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health. Founded in 2025 by Jorn Jansen Schoonhoven (CEO) and Patricio Fernández (CTO), Cori Clinical creates a 'living blueprint' for trials, integrating internal knowledge with external data from registries and regulatory bodies like FDA, MHRA, and EMA. The startup claims its approach could reduce average trial set-up costs by at least 33%. It already works with two of the top five global CROs and has customers like Erasmus MC.
- Cori Clinical raised €3.8 million in a Seed round led by Breega.
- Participants include Enzo, Heartfelt, Together Ventures, and Bynd.
- Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health.
SFC Capital
Recent Signals
- ·EU-Startups (European Venture)Generative Engine Optimization
Obsero Raises €1M for AI Search Visibility
London-based AI search platform and consultancy Obsero has raised €1 million ($1.2 million) in Seed funding. The round was led by SFC Capital, with participation from several of Obsero's own customers. The funds will be used to develop specialist AI agents trained on their GEO (Generative Engine Optimization) playbook, double the engineering team, and accelerate go-to-market efforts. Obsero helps brands improve visibility in AI assistants like ChatGPT, Gemini, Perplexity, and Google's AI Overviews. In its first year, the company has tracked over 10 million AI answers. Clients include Zopa Bank and Pepperstone, with agency partners IDHL and Silverbean. The funding reflects growing investment in AI search visibility startups across Europe.
- Obsero, a British AI search platform and consultancy, raised €1 million ($1.2 million) in Seed funding.
- The round was led by SFC Capital, with participation from several of Obsero's own customers.
- Obsero plans to develop specialist AI agents, double its engineering team, and accelerate GTM.
- ·Tech.eu (European Tech & Deals)Healthcare AI
Anemo Labs Raises £700K for AI E-Nose
London-based deeptech startup Anemo Labs has raised £700,000 in pre-seed funding to develop an electronic nose (e-nose) that combines sensor hardware with AI to detect volatile organic compounds (VOCs). The round was led by Zinc and SFC Capital with support from Innovate UK. Founded in 2025 by Koye Sodipo, the company initially targets healthcare applications, analyzing VOCs from urine for non-invasive disease screening. Anemo's in-house sampling platform can collect and label up to 5,000 smells daily, and early tests using the Sniffin' Sticks protocol achieved 84.15% accuracy across 12 scent categories. The funding will advance sensor chemistry, expand data collection, and support clinical validation.
- Anemo Labs raised £700,000 in pre-seed funding.
- The funding round was led by Zinc and SFC Capital, with support from Innovate UK.
- Anemo Labs is developing an electronic nose combining sensor hardware and AI to detect VOCs.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Breega and SFC Capital share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks